Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells

Anna Adhikari, Nycole A. Copping, Julie Beegle, David L. Cameron, Peter Deng, Henriette O'Geen, David J. Segal, Kyle D. Fink, Jill L. Silverman, Joseph S. Anderson

Research output: Contribution to journalArticlepeer-review

Abstract

Angelman syndrome (AS) is a rare neurodevelopmental disorder characterized by impaired communication skills, ataxia, motor and balance deficits, intellectual disabilities, and seizures. The genetic cause of AS is the neuronal loss of UBE3A expression in the brain. A novel approach, described here, is a stem cell gene therapy which uses lentivector-transduced hematopoietic stem and progenitor cells to deliver functional UBE3A to affected cells. We have demonstrated both the prevention and reversal of AS phenotypes upon transplantation and engraftment of human CD34+ cells transduced with a Ube3a lentivector in a novel immunodeficient Ube3amat-/pat+ IL2rg-/y mouse model of AS. A significant improvement in motor and cognitive behavioral assays as well as normalized delta power measured by electroencephalogram was observed in neonates and adults transplanted with the gene modified cells. Human hematopoietic profiles observed in the lymphoid organs by detection of human immune cells were normal. Expression of UBE3A was detected in the brains of the adult treatment group following immunohistochemical staining illustrating engraftment of the gene-modified cells expressing UBE3A in the brain. As demonstrated with our data, this stem cell gene therapy approach offers a promising treatment strategy for AS, not requiring a critical treatment window.

Original languageEnglish (US)
Pages (from-to)1067-1083
Number of pages17
JournalHuman molecular genetics
Volume30
Issue number12
DOIs
StatePublished - Jun 15 2021

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells'. Together they form a unique fingerprint.

Cite this